Licensing & partnership

Boehringer pays $358M upfront for options on six Sino Biopharm cancer biologics

Boehringer Ingelheim signed an option and licence pact with Sino Biopharmaceutical Limited covering six preclinical biologics, five originating at LaNova Medicines. Upfront and near-term payments total $358 million, with as much as $7 billion more in option and milestone fees plus tiered double-digit royalties. Sino Biopharm will run development through global phase 1 before Boehringer decides on each option.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call